Longitudinal Effects of Modified Creatinine Index on All-cause Mortality in Individuals Receiving Hemodialysis Treatment

Overview

Journal Ann Saudi Med

Specialty General Medicine

Date 2021 Dec 7

PMID 34873933

Authors

Koray Uludag

Tamer Arikan

Affiliations

Soon will be listed here.

Abstract

Background: The modified creatinine index (mCI), as a surrogate marker of muscle mass, has been associated with poor outcomes in patients undergoing hemodialysis. However, a single assessment may not reflect the clinical significance before an adverse clinical endpoint.

Objective: Analyze mCI trajectories and their association with all-cause mortality in incident hemodialysis patients.

Design: Retrospective observational cohort.

Setting: Outpatient dialysis facility.

Patients And Methods: We followed a cohort of patients who underwent maintenance hemodialysis treatment at least three times weekly for at least three months from 19 June 2010 to 29 December 2017. Clinical and laboratory features were measured at baseline. Longitudinal changes in the mCI were modeled using a joint longitudinal and survival model adjusted for baseline covariates and body mass index trajectories.

Main Outcome Measure: All-cause mortality.

Sample Size: 408 with 208 males (50.7%).

Results: The mean (SD) age was 62.2 (12.3) years. The mCI changes were evaluated for a median (interquartile range) follow-up of 2.16 (1.13, 3.73) years. Forty-six percent (n=188) of patients reached the endpoint. A steeper slope (per 0.1 unit increase in the decrease rate) in modified creatinine index was associated with increased risk of all-cause mortality (HR, 1.04; 95% CI, 1.02-1.07; =.011). In addition, an annual 1 mg/kg/day decrease in modified creatinine index level increased the hazard of all-cause mortality by 4% (HR, 1.04; 95% CI, 1.02-1.07; =.001).

Limitations: Residual kidney function was not observed in the data. Setting was single center and thus results may not be generalizable to other populations.

Conclusion: All-cause death was significantly associated with loss of muscle mass over time. Longitudinal trajectories of nutritional markers may predict the clinical outcomes in patients undergoing hemodialysis. This may also be valuable for individual risk stratification. Furthermore, early management may provide an opportunity to improve patient survival.

Conflict Of Interest: None.

References

Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J . Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013; 144(7):1426-37, 1437.e1-9. DOI: 10.1053/j.gastro.2013.02.042. View

Garg V, Garg H, Khan A, Trehanpati N, Kumar A, Sharma B . Granulocyte colony-stimulating factor mobilizes CD34(+) cells and improves survival of patients with acute-on-chronic liver failure. Gastroenterology. 2011; 142(3):505-512.e1. DOI: 10.1053/j.gastro.2011.11.027. View

Gustot T . Beneficial role of G-CSF in acute-on-chronic liver failure: effects on liver regeneration, inflammation/immunoparalysis or both?. Liver Int. 2014; 34(4):484-6. DOI: 10.1111/liv.12356. View

Theocharis S, Agapitos E, Margeli A, Goutas N, Kittas C, Davaris P . Effect of two forms of granulocyte-colony-stimulating factor on hepatic regeneration after 70% partial hepatectomy in rats. Clin Sci (Lond). 1997; 92(3):315-20. DOI: 10.1042/cs0920315. View

Kimura M, Yamada T, Iwata H, Sekino T, Shirahashi K, Yoshida N . Preoperative granulocyte-colony stimulating factor (G-CSF) treatment improves congested liver regeneration. J Surg Res. 2009; 158(1):132-7. DOI: 10.1016/j.jss.2008.09.002. View

Zhao J, Zhang J, Yu H, He Y, Zhao J, Li J . Improved survival ratios correlate with myeloid dendritic cell restoration in acute-on-chronic liver failure patients receiving methylprednisolone therapy. Cell Mol Immunol. 2012; 9(5):417-22. PMC: 4002325. DOI: 10.1038/cmi.2011.51. View

Piscaglia A, Shupe T, Oh S, Gasbarrini A, Petersen B . Granulocyte-colony stimulating factor promotes liver repair and induces oval cell migration and proliferation in rats. Gastroenterology. 2007; 133(2):619-31. PMC: 3130597. DOI: 10.1053/j.gastro.2007.05.018. View

Duan X, Liu F, Tong J, Yang H, Chen J, Liu X . Granulocyte-colony stimulating factor therapy improves survival in patients with hepatitis B virus-associated acute-on-chronic liver failure. World J Gastroenterol. 2013; 19(7):1104-10. PMC: 3581999. DOI: 10.3748/wjg.v19.i7.1104. View

Wang Y, Ma L, Ji R . [Advances on mechanisms and application of granulocyte colony-stimulating factor in treatment of liver failure]. Zhonghua Nei Ke Za Zhi. 2017; 56(12):954-957. DOI: 10.3760/cma.j.issn.0578-1426.2017.12.015. View

10.

Ohnishi H, SUGIHARA J, Moriwaki H, Muto Y . [Acute-on-chronic liver failure]. Ryoikibetsu Shokogun Shirizu. 1995; (7):217-9. View

11.

Wasmuth H, Kunz D, Yagmur E, Timmer-Stranghoner A, Vidacek D, Siewert E . Patients with acute on chronic liver failure display "sepsis-like" immune paralysis. J Hepatol. 2005; 42(2):195-201. DOI: 10.1016/j.jhep.2004.10.019. View

12.

Gianni A, Siena S, Bregni M, Tarella C, Stern A, Pileri A . Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet. 1989; 2(8663):580-5. DOI: 10.1016/s0140-6736(89)90711-3. View

13.

Than N, Newsome P . Stem cells for liver regeneration. QJM. 2014; 107(6):417-21. DOI: 10.1093/qjmed/hcu013. View

14.

Sarin S, Choudhury A, Sharma M, Maiwall R, Al Mahtab M, Rahman S . Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. Hepatol Int. 2019; 13(4):353-390. PMC: 6728300. DOI: 10.1007/s12072-019-09946-3. View

15.

Singh V, Sharma A, Narasimhan R, Bhalla A, Sharma N, Sharma R . Granulocyte colony-stimulating factor in severe alcoholic hepatitis: a randomized pilot study. Am J Gastroenterol. 2014; 109(9):1417-23. DOI: 10.1038/ajg.2014.154. View

16.

Mookerjee R, Stadlbauer V, Lidder S, Wright G, Hodges S, Davies N . Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome. Hepatology. 2007; 46(3):831-40. DOI: 10.1002/hep.21737. View

17.

Lin S, Zhang K, Zhang J, Wang M, Velani B, Zhu Y . Long-term outcomes of patients with hepatitis B virus-related acute on chronic liver failure: An observational cohort study. Liver Int. 2019; 39(5):854-860. DOI: 10.1111/liv.14072. View

18.

Shasthry S, Sharma M, Shasthry V, Pande A, Sarin S . Efficacy of Granulocyte Colony-stimulating Factor in the Management of Steroid-Nonresponsive Severe Alcoholic Hepatitis: A Double-Blind Randomized Controlled Trial. Hepatology. 2019; 70(3):802-811. DOI: 10.1002/hep.30516. View

19.

Modares N, Polz R, Haghighi F, Lamertz L, Behnke K, Zhuang Y . IL-6 Trans-signaling Controls Liver Regeneration After Partial Hepatectomy. Hepatology. 2019; 70(6):2075-2091. DOI: 10.1002/hep.30774. View

20.

Abdallah M, Waleed M, Bell M, Nelson M, Wong R, Sundaram V . Systematic review with meta-analysis: liver transplant provides survival benefit in patients with acute on chronic liver failure. Aliment Pharmacol Ther. 2020; 52(2):222-232. DOI: 10.1111/apt.15793. View